ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Hasan, Md Kamrul ^a,b   Nafady, Asmaa ^a,c   Takatori, Atsushi ^a   Kishida, Satoshi ^d   Ohira, Miki ^a   Suenaga, Yusuke ^a   Hossain, Shamim ^a   Akter, Jesmin ^a   Ogura, Atsushi ^a   Nakamura, Yohko ^a   Kadomatsu, Kenji ^d   Nakagawara, Akira ^a,b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Assiut University Faculty of Medicine   (Egypt)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; MESSENGER RNA; MYC PROTEIN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DISEASE MODEL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; NEUROBLASTOMA; ONCOGENE; PATHOLOGY; TUMOR INVASION; XENOGRAFT;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, MESSENGER;

EID: 84890949034     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03450     Document Type: Article

References (44)

1. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216 (2003). (Pubitemid 37328872)
2. Nakagawara, A. et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 328, 847-854 (1993). (Pubitemid 23084339)
3. Ogawa, S., Takita, J., Sanada, M. & Hayashi, Y. Oncogenic mutations of ALK in neuroblastoma. Cancer Sci. 102, 302-308 (2011).
4. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121-4 (1984). (Pubitemid 14106392)
5. Seeger, R. C. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 13, 1111-6 (1985). (Pubitemid 16216827)
6. Kohl, N. E., Gee, C. E. & Alt, F. W. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 226, 1335-7 (1984). (Pubitemid 15215589)
7. Riley, R. D. et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin. Cancer Res. 10, 4-12 (2004). (Pubitemid 38114154)
8. Lutz, W. et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13, 803-12 (1996). (Pubitemid 26312908)
9. Bernards, R., Dessain, S. K. &Weinberg, R. A. N-myc amplification causes downmodulation of MHC class I antigen expression in neuroblastoma. Cell 47, 667-74 (1986). (Pubitemid 17011410)
10. Goodman, L. A. et al. Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin. Exp. Met. 15, 130-139 (1997). (Pubitemid 27157815)
11. Tanaka, N. & Fukuzawa, M. MYCN downregulates integrin alpha1 to promote invasion of human neuroblastoma cells. Int. J. Oncol. 33, 815-2 (2008).
12. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G. & Bishop, J. M. Targeted expression ofMYCNcauses neuroblastoma in transgenic mice. EMBO J. 16, 2985-95 (1997). (Pubitemid 27234938)
13. Alex, R., Sozeri, O., Meyer, S. & Dildrop, R. Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res. 20, 2257-63 (1992).
14. Blackwood, E. M. & Eisenman, R. N. Regulation of Myc: Max complex formation and its potential role in cell proliferation. Tohoku J. Exp. Med. 168, 195-202 (1992).
15. Torres, R., Schreiber-Agus, N., Morgenbesser, S. D. & DePinho, R. A. Myc and Max: a putative transcriptional complex in search of a cellular target. Curr. Opin. Cell Biol. 4, 468-74 (1992).
16. De Preter, K. et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol. 7, R84 (2006).
17. Osajima-Hakomori, Y. et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am. J. Pathol. 167, 213-22 (2005). (Pubitemid 40884782)
18. Chen, Y. et al.Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
19. George, R. E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
20. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
21. Mosse, Y. P. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-5 (2008).
22. Caren, H., Abel, F., Kogner, P. & Martinsson, T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem. J. 416, 153-159 (2008).
23. Passoni, L. et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 69, 7338-7346 (2009).
24. Duijkers, F. A. et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. Am. J. Pathol. 180, 1223-3 (2012).
25. De Brouwer, S. et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16, 4353-62 (2010).
26. Schulte, J. H. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin. Cancer Res. 17, 5082-92 (2011).
27. Di Paolo, D. et al. Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol. Ther. 19, 2201-12 (2011).
28. Banerjee, S. A.,Hoppe, P., Brilliant, M.&Chikaraishi, D. M. 59 Flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and trans synaptic expression in transgenic mice. J. Neurosci. 12, 4460-4467 (1992).
29. Akter, J. et al. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Clin. Cancer Res. 17, 6681-92 (2011).
30. Moog-Lutz, C. et al. Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Bio. Chem. 280, 26039-26048 (2005). (Pubitemid 41022195)
31. Thiele, C. J., Reynolds, C. P. & Israel, M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313, 404-406 (1985). (Pubitemid 15198727)
32. Ichimiya, S. et al. Downregulation of hASH1 is associated with the retinoic acidinduced differentiation of human neuroblastoma cell lines. Med. Pediatr. Oncol. 36, 132-4 (2001).
33. Futami, H. & Sakai, R. All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK. Cancer Let. 297, 220-225 (2010).
34. Grandori, C. & Eisenman, R. N. Myc target genes. Trends Biochem. Sci. 22, 177-181 (1997). (Pubitemid 27199319)
35. Bachetti, T. et al. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLoS One 5, e13108 (2010).
36. Schonheer, C. et al. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells. Oncogene 31, 5193-5200 (2012).
37. Berry, T. et al. The ALKF1174L mutation potentiates the oncogenic activity ofMYCN in neuroblastoma. Cancer Cell 22, 117-130 (2012).
38. Brodeur, G. M. et al. Revisions of the international criteria for neuroblastoma. Diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466-77 (1993). (Pubitemid 23228250)
39. Huang, P. et al. The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma. Cancer Res. 71, 2938-48 (2011).
40. Hossain, S. et al. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo. Cancer Res. 72, 4587-96 (2012).
41. Galkin, A. V. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc. Natl. Acad. Sci. USA 104, 270-275 (2007). (Pubitemid 46068021)
42. Heukamp, L.C. et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci. Trans. Med. 4, 141ra91 (2012).
43. Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679-690 (2011).
44. Christensen, J. G. et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-22 (2007).